The therapeutic potential of mTOR inhibitors in breast cancer

Rapamycin and modified rapamycins (rapalogs) have been used to prevent allograft rejection after organ transplant for over 15 years. The mechanistic target of rapamycin (mTOR) has been determined to be a key component of the mTORC1 complex which consists of the serine/threonine kinase TOR and at lea...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Br J Clin Pharmacol
Huvudupphovsmän: Steelman, Linda S., Martelli, Alberto M., Cocco, Lucio, Libra, Massimo, Nicoletti, Ferdinando, Abrams, Stephen L., McCubrey, James A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2016
Ämnen:
Review‐themed Issue
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5061784/
https://ncbi.nlm.nih.gov/pubmed/27059645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12958
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk